Axsome v. Unichem: Solriamfetol Patent Dispute Consolidated Into Multi-Defendant Action
Axsome Malta and Axsome Therapeutics filed suit against Unichem Laboratories in the District of New Jersey, asserting five patents covering solriamfetol formulations and methods for treating sleep-wake disorders. The case was consolidated within 155 days into a broader eight-action proceeding encompassing all major generic challengers, including Alkem, Aurobindo, Hetero, Hikma, and Sandoz.
Axsome’s Solriamfetol Patent Portfolio Draws Multi-Front ANDA Challenge
On December 20, 2023, Axsome Malta Ltd. and Axsome Therapeutics, Inc. filed Civil Action No. 2:23-cv-23255 in the District of New Jersey against Unichem Laboratories Ltd., asserting five U.S. patents — US11779554B1, US11753368B2, US11771666B1, US11771667B1, and US11793776B1 — covering methods of administering solriamfetol to lactating women and the treatment of sleep-wake disorders. Solriamfetol (marketed as Sunosi) is a dopamine and norepinephrine reuptake inhibitor approved for excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea.
On May 23, 2024, after just 155 days, the case was terminated not on the merits but through consolidation with seven related civil actions filed in the same district. The court ordered all proceedings — including Civil Action Nos. 23-20354, 23-23255, 24-196, 24-309, 24-860, 24-3999, 24-4002, and 24-4608 — to be merged into a single consolidated action for discovery, case management, and trial. This procedural outcome means the Unichem-specific docket closes, but the underlying patent claims against Unichem proceed within the consolidated framework.
The speed of consolidation — under six months from the Unichem filing — is consistent with active judicial management in crowded ANDA dockets, where parallel suits against multiple generic filers are routinely merged to avoid duplicative discovery and inconsistent rulings. The public record does not disclose any substantive merits ruling, claim construction briefing, or settlement terms; the outcome of the patent dispute against Unichem remains to be resolved within the consolidated action. The breadth of defendants named across the eight actions suggests Axsome is mounting a coordinated Hatch-Waxman defense of its solriamfetol IP estate.
Filing to Case Consolidated in 155 days
155 days from filing to consolidation — typical ANDA consolidation can extend 6–12 months
Case consolidated: what the court’s order means for both parties
Consolidation merges cases, it does not end the dispute
Under Federal Rule of Civil Procedure 42(a), courts may consolidate actions sharing common questions of law or fact. Here, the court merged eight related ANDA infringement suits into one coordinated proceeding. Unichem’s case (No. 23-23255) is administratively closed, but all claims against Unichem survive and continue under the consolidated docket. No merits ruling has been issued.
FRCP Rule 42(a) consolidationAxsome retains all claims against Unichem in consolidated forum
Consolidation is strategically neutral-to-positive for Axsome. The company can prosecute its five solriamfetol patents against all generic challengers — including Unichem, Alkem, Aurobindo, Hetero, Hikma, and Sandoz — in a single coordinated action. This reduces duplicative litigation costs and ensures consistent claim construction rulings apply to all defendants simultaneously.
Claims preserved — no concessionUnichem now faces consolidated defense alongside five other generics
For Unichem, consolidation means its ANDA challenge will be adjudicated alongside those of several larger generic manufacturers. While this may offer cost-sharing opportunities in joint discovery, Unichem loses the ability to pursue independent claim construction or scheduling advantages. Any adverse ruling in the consolidated action on patent validity or infringement will apply to Unichem’s ANDA as well.
Shared risk in consolidated actionCoordinated Hatch-Waxman defense signals strong Axsome IP posture
The consolidation of eight actions covering solriamfetol suggests Axsome’s IP estate attracted simultaneous ANDA challenges from multiple generic manufacturers — a common pattern for commercially significant CNS drugs. The consolidated proceeding will produce a single set of claim construction rulings and validity findings, making the outcome a high-stakes determinant of generic entry timing for the entire solriamfetol market.
Generic entry timeline at stakeFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Axsome Malta, Ltd. | Company | Pharmaceutical IP holder — asserting US11779554B1 and 4 related solriamfetol patentsSearch in Eureka ↗ |
| Co-Plaintiff | Axsome Therapeutics, Inc. | Company | Search in Eureka ↗ |
| Defendant | Unichem Laboratories, Ltd. | Company | Indian generic pharmaceutical manufacturer and ANDA filer challenging solriamfetol patentsSearch in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Charles Michael Lizza | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Sarah Ann Sullvian | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing Axsome Malta, Ltd.Search in Eureka ↗ |
| Defendant counsel | R. Touhey Myer | Attorney | Counsel for Unichem Laboratories, Ltd.Search in Eureka ↗ |
| Defendant law firm | Kratz & Barry, LLP | Law Firm | Representing Unichem Laboratories, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated consolidation order reflects a procedural alignment between Axsome and all named defendants, rather than any merits adjudication. The order’s language — consolidating all actions ‘for all purposes, including discovery, case management, and trial’ — is broad and suggests the court intends a single coordinated proceeding rather than bifurcated handling. No admissions of infringement or validity are implied. Both Axsome’s patent claims and Unichem’s ANDA challenge remain live within the consolidated framework.
US11779554B1 — Solriamfetol administration methods and sleep-wake disorder treatment
The five asserted patents — US11779554B1, US11753368B2, US11771666B1, US11771667B1, and US11793776B1 — collectively cover methods of administering solriamfetol, including to specific patient populations such as lactating women, and the treatment of sleep-wake disorders including narcolepsy and obstructive sleep apnea-related excessive daytime sleepiness. The application numbers indicate these patents were prosecuted through continuation filings in the US18/176xxx and US17/034xxx series, suggesting a coordinated prosecution strategy building claim depth around the Sunosi commercial product.
From a competitive intelligence perspective, this five-patent cluster represents Axsome’s secondary exclusivity strategy — layering method-of-use and population-specific claims on top of any compound patents to extend the effective exclusivity period of solriamfetol. For generic manufacturers, each patent represents an independent invalidity or non-infringement argument that must be addressed in the ANDA filing. The population-specific claims (lactating women) are particularly notable as they may be harder to design around without clinical data and are less frequently challenged in IPR proceedings.
Should you run an FTO analysis against Axsome’s solriamfetol patent cluster?
Any company developing wakefulness-promoting agents, dopamine/norepinephrine reuptake inhibitors, or filing ANDAs for solriamfetol or structurally related compounds should treat Axsome’s five-patent estate as a primary FTO concern. The method-of-use claims covering sleep-wake disorder treatment are broad enough to implicate label language as well as formulation, and the population-specific claims covering lactating women create a secondary clearance requirement that is easily overlooked in standard FTO workflows.
PatSnap Eureka’s FTO Search Agent enables R&D and regulatory teams to map each of the five asserted patents against proposed product claims, ANDA label language, and comparable prior art landscapes. Eureka’s claim-level analysis surfaces the specific independent claims that pose the highest infringement risk and identifies prosecution history estoppel that may narrow each patent’s scope — critical intelligence before any ANDA filing or product launch decision in the solriamfetol or wakefulness therapy space.
Run a freedom-to-operate analysis on US11779554B1 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman Cases: Solriamfetol and CNS Sleep Disorder Patents in D.N.J.
Related ANDA patent infringement cases involving CNS and sleep-wake disorder drugs litigated in the District of New Jersey, including solriamfetol and dopamine reuptake inhibitor patent disputes.
What this case signals for the CNS drug and Hatch-Waxman IP landscape
Axsome’s coordinated multi-defendant litigation over solriamfetol illustrates the high-stakes IP dynamics surrounding specialty CNS sleep disorder therapies.
Five-patent assertion strategy raises the invalidation bar for all challengers
Axsome asserted five patents across methods of administration, dosing in specific populations, and sleep-wake disorder treatment. Generic challengers must successfully invalidate or design around each patent to achieve clearance for ANDA approval, substantially increasing the cost and complexity of any challenge.
Consolidation signals judicial efficiency — but also higher trial stakes
When a district court consolidates eight related ANDA suits, the resulting single trial becomes a definitive ruling affecting all generic market entrants simultaneously. Patent holders and defendants alike face concentrated risk — a single adverse ruling on validity could open or close the entire market.
Axsome v Unichem — key questions answered
The case was consolidated on May 23, 2024, approximately 155 days after filing. The court merged Civil Action No. 2:23-cv-23255 with seven related solriamfetol ANDA infringement actions into a single consolidated proceeding. No merits ruling was issued — Axsome’s patent claims against Unichem continue within the consolidated docket.
Axsome asserted five U.S. patents: US11779554B1, US11753368B2, US11771666B1, US11771667B1, and US11793776B1. These patents cover methods of administering solriamfetol, including to lactating women, and treatment of sleep-wake disorders such as narcolepsy and obstructive sleep apnea-related excessive daytime sleepiness.
Consolidation under FRCP Rule 42(a) means the Unichem case is administratively merged with seven related actions but is not dismissed. All of Axsome’s patent claims against Unichem remain active and will be adjudicated in the consolidated proceeding. Unichem’s ANDA challenge survives but will be resolved alongside challenges from Alkem, Aurobindo, Hetero, Hikma, and Sandoz.
The consolidated action includes eight civil actions against Alkem Laboratories Ltd., Aurobindo Pharma USA and Aurobindo Pharma Limited, Hetero USA Inc. and Hetero Labs (multiple entities), Hikma Pharmaceuticals USA Inc., Sandoz Inc., and Unichem Laboratories Ltd. The consolidation order covers Civil Action Nos. 23-20354, 23-23255, 24-196, 24-309, 24-860, 24-3999, 24-4002, and 24-4608.
Solriamfetol (brand name Sunosi) is a dopamine and norepinephrine reuptake inhibitor approved for treating excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea. As a commercially significant CNS drug, it attracted simultaneous ANDA filings from multiple generic manufacturers, triggering a coordinated Hatch-Waxman patent infringement response from Axsome, the patent holder.
PatSnap Eureka searches patents and litigation data to answer instantly.